Neurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 4,200 Shares of Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,200 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the completion of the sale, the chief financial officer owned 84,040 shares in the company, valued at approximately $3,036,365.20. The trade was a 4.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Monday, July 6th, Christine Mikail Cvijic sold 600 shares of Neurogene stock. The stock was sold at an average price of $36.02, for a total transaction of $21,612.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total transaction of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The shares were sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total value of $300,000.00.

Neurogene Trading Up 13.0%

NGNE traded up $4.24 on Tuesday, hitting $36.80. 708,181 shares of the stock traded hands, compared to its average volume of 246,656. Neurogene Inc. has a 52 week low of $15.93 and a 52 week high of $37.27. The firm has a market capitalization of $581.44 million, a PE ratio of -8.09 and a beta of 1.68. The business has a fifty day moving average price of $29.70 and a two-hundred day moving average price of $23.57.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). On average, equities research analysts forecast that Neurogene Inc. will post -5.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Neurogene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NGNE. Balyasny Asset Management L.P. acquired a new position in shares of Neurogene during the third quarter worth about $12,114,000. Logos Global Management LP acquired a new position in Neurogene during the 4th quarter worth approximately $4,017,000. Jennison Associates LLC grew its stake in shares of Neurogene by 35.3% during the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after acquiring an additional 138,999 shares in the last quarter. State Street Corp grew its stake in shares of Neurogene by 47.8% during the 4th quarter. State Street Corp now owns 307,797 shares of the company’s stock worth $6,341,000 after acquiring an additional 99,487 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Neurogene by 122.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 162,018 shares of the company’s stock valued at $3,338,000 after purchasing an additional 89,216 shares during the last quarter. Institutional investors own 52.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a research note on Tuesday, June 9th. Guggenheim began coverage on shares of Neurogene in a report on Tuesday, April 28th. They set a “buy” rating and a $69.00 price target for the company. UBS Group set a $70.00 price target on shares of Neurogene in a research report on Wednesday, June 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. Finally, Canaccord Genuity Group reduced their target price on Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $84.83.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.